Antigen News and Research

RSS

CureVac begins phase I study to assess intratumoral application of RNAdjuvant technology in patients with solid tumors

CureVac AG, a fully-integrated biotechnology company pioneering mRNA-based drugs, today announced it has initiated a Phase I study assessing the intratumoral application of its novel RNAdjuvant technology in patients with superficial solid tumors that are easily accessible for repeated intratumoral injections. RNAdjuvant is designed to amplify the scope and quality of an immune response when used alone or in combination with other immune therapies.

28 Oct 2017

New device that fits on a key chain can accurately test for allergens

More than 50 million Americans have food allergies and often just trace amounts of allergens can trigger life-threatening reactions.

26 Oct 2017

What men need to know: Prevention, diagnosis, and treatment of prostate cancer

Prostate cancer is the second leading cause of cancer death in men. Next to skin cancers, prostate cancer is the most common cancer diagnosed in American men.

25 Oct 2017

VICC selected to administer FDA-approved CAR T therapy for treatment of lymphoma patients

Vanderbilt-Ingram Cancer Center has been selected as one of the few authorized treatment centers in the United States approved to administer the first FDA- approved chimeric antigen receptor T cell (CAR T) therapy for treatment of adult patients with a specific type of lymphoma.

25 Oct 2017

Researchers develop new way to genetically engineer T cells for treating leukemia relapse

Researchers at Fred Hutchinson Cancer Research Center and the University of Washington have developed a novel way to genetically engineer T cells that may be effective for treating and preventing leukemia relapse.

25 Oct 2017

Study discovers new genetic risk loci linked to children's food allergies

What role do genes play in egg, milk, and nut allergies? A study published in Nature Communications, led by the Max Delbrück Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, has found five genetic risk loci that point to the importance of skin and mucous membrane barriers and the immune system in the development of food allergies.

24 Oct 2017

Study provides deeper understanding on mechanisms of lipid-based autoimmune disease

Phospholipids - fat molecules that form the membranes found around cells - make up almost half of the dry weight of cells, but when it comes to autoimmune diseases, their role has largely been overlooked.

20 Oct 2017

Pharmacological stimulation of nicotinic receptor could be strategy to treat lung inflammation

It has been amply proven that smoking can cause serious diseases such as emphysema and cancer. A new study, however, shows that pharmacological stimulation of a specific type of nicotinic receptor in cells of the immune system could be a strategy to treat inflammatory lung disease.

20 Oct 2017

Dana-Farber, Brigham and Women's Cancer Center certified to offer new CAR T-cell therapy

Following a successful clinical trial involving Dana-Farber Cancer Institute and Brigham and Women's Hospital, the first chimeric antigen receptor (CAR) T-cell therapy for adult cancers was approved by the Food and Drug Administration today.

20 Oct 2017

New CAR-T cell therapy offers effective option for certain blood cancer patients

Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis is one of the first centers nationwide to offer a new immunotherapy that targets certain blood cancers.

19 Oct 2017

Scientists receive critical funding to study treatments for three deadly cancers

Immunotherapy for leukemia patients has been nothing short of a miracle. Now scientists hope to use that science and other forms of gene therapy to tackle three of the deadliest forms of cancer: glioblastoma (brain cancer), sarcoma (bone cancer) and ovarian cancer.

17 Oct 2017

CGT Catapult’s iPSC line licensed to Universal Cells for creating universal donor cell line

The Cell and Gene Therapy Catapult today announced a non-exclusive licensing agreement to provide its clinical-grade induced Pluripotent Stem Cell line to Seattle based Universal Cells.

6 Oct 2017

New DNA-based Zika vaccine demonstrates safety and ability to elicit immune response

A new generation DNA-based Zika vaccine is the first to demonstrate both safety and the ability to elicit an immune response against Zika in humans, according to new research from the Perelman School of Medicine at the University of Pennsylvania, conducted in partnership with The Wistar Institute, Inovio Pharmaceuticals, and GeneOne Life Science, Inc.

5 Oct 2017

New gene therapy to treat cancer in children, young adults offers hopes and challenges

The first gene therapy for cancer, approved by the Food Drug Administration in August, will transform the treatment of a particular kind of cancer in children and young adults. It's transformative because it uses a patient's own immune cells to attack the cancer cells.

3 Oct 2017

Cancer vaccines need to target immune fighters that can withstand battle against malicious tumors

Cancer vaccines may need to better target T cells that can hold up to the long fight against cancer, scientists report.

27 Sep 2017

UTSA professor awarded grant to support development of prostate cancer detection method

Jing Yong Ye, professor of biomedical engineering at The University of Texas at San Antonio (UTSA), has received a two-year, $354,617 grant from the National Institutes of Health's National Cancer Institute to support the development of his noninvasive method of detecting prostate cancer.

25 Sep 2017

Antigen News and Research

CureVac begins phase I study to assess intratumoral application of RNAdjuvant technology in patients with solid tumors

New device that fits on a key chain can accurately test for allergens

What men need to know: Prevention, diagnosis, and treatment of prostate cancer

VICC selected to administer FDA-approved CAR T therapy for treatment of lymphoma patients

Researchers develop new way to genetically engineer T cells for treating leukemia relapse

Study discovers new genetic risk loci linked to children's food allergies

Study provides deeper understanding on mechanisms of lipid-based autoimmune disease

Pharmacological stimulation of nicotinic receptor could be strategy to treat lung inflammation

Dana-Farber, Brigham and Women's Cancer Center certified to offer new CAR T-cell therapy

New CAR-T cell therapy offers effective option for certain blood cancer patients

Scientists receive critical funding to study treatments for three deadly cancers

CGT Catapult’s iPSC line licensed to Universal Cells for creating universal donor cell line

New DNA-based Zika vaccine demonstrates safety and ability to elicit immune response

New gene therapy to treat cancer in children, young adults offers hopes and challenges

Cancer vaccines need to target immune fighters that can withstand battle against malicious tumors

UTSA professor awarded grant to support development of prostate cancer detection method

“Super malaria” resistant to standard medications in South East Asia

Neurohistology: how whole slide scanning impacts workflow

Researchers design novel small antibody fragment with improved crystallizability

Poliovirus therapy triggers longer-lasting immune response against malignant tumors

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News